HISTORY OF PLASMA THERAPY: A CURRENTLY USED TREATMENT OPTION FOR COVID-19

Yıl 2021, , 411 - 414, 31.07.2021

Esra Bilir Emine Elif Vatanoğlu Lutz Ayşe Arzu Akalın

https://doi.org/10.26650/IUITFD.2020.0106

Öz

The current pandemic provides the most incredible opportunity to develop convalescent plasma therapy into an effective treatment modality for the coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) while a vaccine is still under development. The global reach of this pandemic, and the immediate need for effective treatments for patients with severe and critical COVID-19, is driving both basic and clinical research at an unprecedented rate. Convalescent plasma therapy is a treatment option that has been known since the 1900s and has been used in various disease treatments since then. Convalescent plasma therapy is one of the treatments currently being used in the treatment of patients with COVID-19. We see that this treatment method was likewise used in MERS, SARS, and Ebola epidemics, which occurred worldwide in the recent past. This review aims to provide an overview of plasma therapy’s history and the scientists behind this vital discovery. Secondarily, we report the recent global advances in convalescent plasma use in COVID-19 treatment.

Anahtar Kelimeler

COVID-19, convalescent plasma therapy, history

PLAZMA TEDAVİSİNİN TARİHİ: COVID-19 ENFEKSİYONU İÇİN GÜNÜMÜZDE KULLANILMAKTA OLAN BİR TEDAVİ SEÇENEĞİ

Öz

İçinde bulunduğumuz mevcut pandemide “Severe Acute Respiratory Syndrome Coronavirus-2” (SARS-CoV-2) virüsünün neden olduğu yeni koronavirüs hastalığı (COVID-19) için aşı geliştirme çalışmaları devam ederken, konvalesan plazma tedavisi de etkili bir tedavi yöntemi olarak bir fırsat sunmaktadır. Bu pandemide, şiddetli ve kritik COVID-19 hastaları için etkili acil tedavilere ihtiyaç duyulmakta, hem temel hem de klinik araştırmalar benzeri görülmemiş bir hızda devam etmekte ve bir çok çalışma konvalesan plazma tedavisine yönlendirmektedir. Konvalesan plazma tedavisi, 1900’lerden beri bilinen ve o zamandan beri çeşitli hastalıklarda kullanılan bir tedavi seçeneğidir. Konvalesan plazma tedavisi halihazırda COVID-19 tanılı hastaların tedavisinde kullanılan tedavi seçeneklerinden birisidir. Yakın geçmişte dünyayı etkisi altına alan MERS, SARS ve Ebola salgınlarında da bu tedavi yönteminin uygulandığını görmekteyiz. Bu derlemede konvalesan plazma tedavisinin tarihçesine ve bu hayati buluşun arkasındaki bilim insanlarına genel bir bakış atmayı amaçlıyoruz. İkincil olarak, COVID-19’un tedavisinde dünyadaki plazma kullanımındaki küresel gelişmeleri sunmak hedeflendi.

Anahtar Kelimeler

COVID-19, konvalesent plazma tedavisi, tarihçe

Kaynakça

• 1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. (cited 2020 August 27), Available from: URL: https://www.who.int/dg/speeches/detail/who-directorgeneral- s-opening-remarks-
• 2. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Lifethreatening COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(5):460-70. doi: 10.1001/jama.2020.10044. Erratum in: JAMA 2020;324(5):519. [CrossRef]
• 3. Kaufmann SHE. Emil von Behring: translational medicine at the dawn of immunology. Nat Rev Immunol 2017;17(6):341- 3. [CrossRef]
• 4. Sanz ML. Legends of Allergy/Immunology: Albert K. Oehling. Allergy 2019;74(2):382-4. [CrossRef]
• 5. Gmelig-Meyling FH, Meyaard L, Mebius RE. 50 years of Dutch immunology--founders, institutions, highlights. Immunol Lett. 2014;162(2 Pt B):85-94. doi: 10.1016/j. imlet.2014.10.014. Epub 2014 Oct 16. Erratum in: Immunol Lett. 2015 May;165(1):62. [CrossRef]
• 6. The Nobel Prize in Physiology or Medicine 1972. (cited 2020 August 27), Available from: URL: https://www.nobelprize. org/prizes/medicine/1972/summary/.
• 7. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130(6):2757-65. [CrossRef]
• 8. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005;24(1):44-6. [CrossRef]
• 9. McIntosh, K. Middle East respiratory syndrome coronavirus: Treatment and prevention. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (cited 2020 September 12)
• 10. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016;374(1):33-42. [CrossRef]
• 11. Centers for Disease Control and Prevention. Review of human-to-human transmission of Ebola virus. (cited 2020 September 12), Available from: URL: http://www.cdc.gov/ vhf/ebola/transmission/human-transmission.html.
• 12. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (based on data as of the 31 December 2003). (cited 2020 September 12), Available from: URL: http://www.who. int/csr/sars/country/table2004_04_21/en/index.html.
• 13. World Health Organization. WHO-ISARIC joint MERS-CoV Outbreak Readiness Workshop: Clinical management and potential use of convalescent plasma. (cited 2020 September 12), Available from: URL: http://www.who. int/csr/disease/coronavirus_infections/MERS_outbreak_ readiness_workshop.pdf.
• 14. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis 2016;22(9):1554-61. [CrossRef]
• 15. Bray M, Chertow DS. Epidemiology and pathogenesis of Ebola virus disease. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (cited 2020 September 12) [CrossRef]
• 16. WHO Coronavirus Disease (COVID-19) Dashboard. (cited 2020 September 12), Available from: URL: https://covid19. who.int.
• 17. US Food and Drug Administration. Emergency use authorization for convalescent plasma. (cited 2020 September 12), Available from: URL: https://www.fda.gov/ media/141477/download.
• 18. US Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma. (cited 2020 September 12), Available from: URL: https://www.fda.gov/ vaccines-blood-biologics/investigational-new-drug-ind-ordevice- exemption-ide-process-cber/recommendationsinvestigational- covid-19-convalescent-plasma.